Contact
searchSearch
HMP Global
Login
Conference Insider

Debates and Updates in Treating Esophageal and GEJ Cancers

10/23/2020
Body

Transcript:

David Ilson, MD, PhD, discusses immunotherapy trial data as well as treatment debates in the esophageal and GEJ cancer space, at the virtual 2020 Great Debates and Updates in GI Malignancies meeting.

Recent News

News
Response-Guided PD-1 Therapy May Support Treatment De-Escalation in Advanced Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study found that limited PD-1 exposure frequently produced durable disease control in patients with locally advanced or resectable cutaneous squamous cell carcinoma, with uncertain incremental benefit from treatment...
A retrospective cohort study...
08/28/2026
Oncology
News
Ivonescimab Plus Chemotherapy Extends PFS After Tyrosine Kinase Inhibitor Progression in EGFR-Mutant Non-Small Cell Lung Cancer
08/28/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi trial showed that ivonescimab plus pemetrexed and carboplatin significantly improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutant non-small cell lung cancer...
Results from the phase 3 HARMONi...
08/28/2026
Oncology
News
Expert Consensus Establishes Imaging Recommendations for High-Risk Cutaneous Squamous Cell Carcinoma
08/28/2026
Emily Estrada
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi consensus established staging and surveillance imaging recommendations for localized cutaneous squamous cell carcinoma, supporting imaging for tumors with at least a 15% risk of metastasis and identifying specific...
A multidisciplinary Delphi...
08/28/2026
Oncology
News
Twice-Daily Radiation Associated With Better Patient-Reported Outcomes in Limited-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported outcomes analysis from NRG-LU005 found that adding atezolizumab to chemoradiation did not significantly reduce clinically meaningful decline at 15 months, while twice-daily radiation was consistently associated with...
A planned patient-reported...
08/27/2026
Oncology
News
Tarlatamab Reduces Symptom Burden and Treatment Side Effects in Extensive-Stage Small Cell Lung Cancer
08/27/2026
Emily Estrada
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from the phase 3 DeLLphi-304 trial showed that tarlatamab delayed deterioration in key cancer-related symptoms and physical functioning while reducing treatment-related side-effect burden compared with standard...
Patient-reported outcomes from...
08/27/2026
Oncology
News
Five-Year KEYNOTE-942 Results Show Durable Benefit With Intismeran Plus Pembrolizumab in Resected Melanoma
08/27/2026
Stephanie Holland
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase 2b KEYNOTE-942 trial showed that intismeran plus pembrolizumab maintained durable improvements in recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in patients with...
Five-year results from the phase...
08/27/2026
Oncology
FDA Approval
FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma
08/26/2026
Emily Estrada
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib for adults with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multiagent systemic therapy after phase 3 RASolute 302 data showed significant...
The FDA approved daraxonrasib...
08/26/2026
Oncology
News
Biomarker-Driven GUIDANCE Trial Targets HRD-Positive Small Cell Lung Cancer With Olaparib Plus Durvalumab
08/25/2026
Stephanie Holland
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is evaluating maintenance olaparib plus durvalumab in homologous recombination deficiency-positive advanced or metastatic small cell lung cancer after first-line chemoimmunotherapy, testing whether prospective...
The phase 2 GUIDANCE trial is...
08/25/2026
Oncology
FDA Approval
FDA Approves Zanidatamab-Based Regimens for First-Line HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/25/2026
Stephanie Holland
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab plus chemotherapy, with or without tislelizumab, for first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma after phase 3 HERIZON-GEA-01 data showed significant...
The FDA approved zanidatamab...
08/25/2026
Oncology
News
ESMO Recommends Daraxonrasib After Chemotherapy for RAS G12–Mutant Metastatic Pancreatic Cancer
08/19/2026
Stephanie Holland
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend daraxonrasib as a second-line treatment after chemotherapy for patients with RAS G12–mutant metastatic pancreatic cancer and ECOG performance status 0 to 1, based on phase 3 improvements in survival, response, and...
ESMO guidelines recommend...
08/19/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use